Can Anti-EGFR Antibodies Turn Colorectal Cancer into Hot Tumors?

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K08755
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55020:Digestive surgery-related
• Research Institution: Yamaguchi University
• Principal Investigator: Tomochika Shinobu 山口大学, 大学院医学系研究科, 助教 (30403679)
• Co-Investigator(Kenkyū-buntansha): 恒富 亮一 山口大学, 医学部附属病院, 講師 (10420514) ; 硲 彰一 山口大学, 医学部, 特別医学研究員 (50253159) ; 鈴木 伸明 山口大学, 大学院医学系研究科, 講師 (50526910) ; 吉田 晋 山口大学, 医学部, 特別医学研究員 (60554805)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 癌

Outline of Final Research Achievements

We investigated the effects of anti-EGFR or anti-VEGF monoclonal antibodies (mAb) on T-cell infiltration and T-cell receptor (TCR) repertoire variation in CRC liver metastases. T-cell infiltrations were approximately 83% (5/6) and 50% (2/4), following treatment with anti-EGFR or anti-VEGF mAb, respectively. TCR repertoire analysis revealed higher clonality and lower diversity of TCR alpha and beta (TRA and TRB) in the anti-VEGF mAb group than that in the anti-EGFR group mAb. Furthermore, the percentage of the common TCR clones between infiltrating T cells and T cells in peripheral blood was significantly lower in the anti-VEGF mAb group compared to that in the anti-EGFR mAb group. In conclusion, the population of T cells infiltrating liver metastases in the anti-VEGF mAB group differed from that in the anti-EGFR mAb group.

Free Research Field

消化器外科

Academic Significance and Societal Importance of the Research Achievements

抗EGFR療法と比較して抗VEGF療法では、癌特異的T細胞浸潤が誘導される可能性が示唆された。本研究からの知見は、mCRCに対するさらなる併用療法を支持する情報を提供するものである。